Botulinum toxin is under clinical development by Huons and currently in Phase III for Upper Limb Muscle Spasticity. According to GlobalData, Phase III drugs for Upper Limb Muscle Spasticity does not have sufficient historical data to build an indication benchmark PTSR for Phase III. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Botulinum toxin LoA Report. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Botulinum toxin overview

Botulinum toxin is under development for the treatment of post stroke upper limb spasticity disorders. It is administered through intramuscular route. The drug candidate acts by targeting synaptosomal associated protein 25 (SNAP25).

Huons overview

Huons a subsidiary of Huons Global Co Ltd, develops and manufactures pharmaceutical drugs and medical device solutions in the areas of central nervous system, sensory organs, antihistamines, circulatory, respiratory, and digestive system, metabolic agents and hormones. Huons is headquartered in Seongnam, Gyeonggi, South Korea.

For a complete picture of Botulinum toxin’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 20 February 2024

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.